LUNG - NASDAQ
Pulmonx Corporation
$1.62
+2.9%Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotPulmonx Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Pulmonx Corporation Income Statement
LUNG • NASDAQ
| Pulmonx Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
90.5M | 83.8M | 68.7M | 53.7M | 48.4M | 32.7M | 32.6M | 20M | |
GROSS PROFIT | ||||||||
(23.4M) | (21.8M) | (17.9M) | (13.8M) | (12.8M) | (11.5M) | (10.2M) | (7.7M) | |
67.1M | 62M | 50.8M | 39.9M | 35.6M | 21.2M | 22.4M | 12.3M | |
OPERATING INCOME | ||||||||
(120.8M) | (119.7M) | (112.7M) | (98.5M) | (82.9M) | (53.5M) | (40.3M) | (27.3M) | |
(101.3M) | (102.1M) | (94.6M) | (83.1M) | (69.9M) | (46.1M) | (34.2M) | (20.3M) | |
(19.5M) | (17.6M) | (18.1M) | (15.4M) | (13.1M) | (7.5M) | (6M) | (7M) | |
-53.7M | -57.7M | -61.9M | -58.6M | -47.3M | -32.3M | -17.8M | -15.1M | |
PRE-TAX INCOME | ||||||||
(3.2M) | (3.5M) | (3.2M) | (1.1M) | (829K) | (3.2M) | (2.3M) | (2.5M) | |
-504K | 1.6M | 2.3M | 463K | -429K | -3M | -1.9M | -2.5M | |
286K | 1.8M | 1.7M | 67K | -1M | 314K | -2.5M | -3.4M | |
-53.4M | -55.9M | -60.3M | -58.6M | -48.3M | -32M | -20.3M | -18.5M | |
NET INCOME | ||||||||
(626K) | (500K) | (571K) | (353K) | (343K) | (213K) | (363K) | (12K) | |
-54M | -56.4M | -60.8M | -58.9M | -48.7M | -32.2M | -20.7M | -18.5M |
SEC Filings
LUNG - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | November 24, 2025 | November 24, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 27, 2025 | October 21, 2025 | 2025 |
Related Guides
Continue your LUNG research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.